

PAPULOSQUAMOUS DISEASES

**Dr. Saleh Al rasheed
Consultant in Dermatology &
Laser Surgery
Assistant Professor - Dermatology Department
College of Medicine
KSU , Riyadh.**

Papulosquamous diseases

are those in which the primary lesions typically consist of papules with scale

The category of papulosquamous disease classically includes :

-Psoriasis

-Lichen planus

-Pityriasis rosea

-Seborrheic dermatitis

-Pityriasis rubra pilaris

-Secondary syphilis

-discoid lupus erythematosus,

-Ichthyosis-

-Miscellaneous (mycosis fungoides,) -

Psoriasis

Prevalence

- Psoriasis occurs in 2%(1-3%) of the world's population
- Equal frequency in males and females
- May occur at any age from infancy to the 10th decade of life
- First signs of psoriasis
 - Females mean age of 27 years
 - Males mean age of 29 years

Prevalence

- Two-thirds of patients have mild disease
- One-third have moderate to severe disease
- Early onset (prior to age 15)
 - Associated with more severe disease
 - More likely to have a positive family history
- Life-long disease
 - Remitting and relapsing unpredictably
 - Spontaneous remissions of up to 5 years have been reported in approximately 5% of patients

Etiology

- **The cause of Ps. is still unknown**
- **The course of Ps. is inconstant**
- **Tendency to recur and to persist**
- **Koebler reaction (phenomenon)**
- **Auspitz sign: is pin point bleeding when a psoriatic scale is removed. (Severe thinning of the epidermis over the tips of dermal papillae)**
- **The psoriatic basal-cell is shed in about 4 days where as normal cell in 28 days**
- **The erythema is due to the dilatation & proliferation of the capillaries in the papillary dermis**


Genetics and Pathogenesis

- Psoriasis and the Immune System
 - The major histocompatibility complex (MHC)
 - Short arm of chromosome 6
 - Histocompatibility Antigens (HLA)
 - HLA-Cw6
 - HLA-B13, -B17, -B37, -Bw16
 - T-lymphocyte-mediated mechanism

Triggering factors>

- Infections– streptococcal pharyngitis/tonsillitis
- Drugs– NSAID, beta blockers, lithium, antimalarials, corticosteroids
- Trauma– Koebner phenomenon
- Pregnancy
- Stress
- Alcohol
- Sunlight– worsening in ~10% of patients although majority beneficial to sun exposure

Psoriasis Triggers



Psoriasis : clinical features

- Well defined & circumscribed plaque
 - Erythematous
 - Silvery scaling
 - Symmetrical
 - Extensors of limbs, scalp, sacral area
- Auspitz's sign:
- light scraping of the scale with a wooden spatula produces multiple bleeding points
 - extreme thinning of the epidermis over the capillary laden dermal papillae

Psoriasis as a Systemic Disease

- Koebner Phenomenon
- Elevated ESR
- Increased uric acid levels → gout
- Mild anemia
- Elevated α_2 -macroglobulin
- Elevated IgA levels
- Increased quantities of Immune Complexes

Clinical Variants of Psoriasis

Clinical Types of Psoriasis

A. Non-pustular Psoriasis

B. Pustular Psoriasis

- **Localized**
- **Generalized**

C. Erythrodermic Psoriasis

D. Psoriatic arthritis

A. Non-pustular Psoriasis

- Chronic Plaque Psoriasis
- Regional Psoriasis
- Scalp Psoriasis
- Palmo-plantar Psoriasis
- Inverse Psoriasis (Flexural)
- Nail Psoriasis
- Guttate Psoriasis

Chronic Plaque Psoriasis

- ~80% of psoriasis
- Characteristic erythematous well defined circumscribed silvery scaly patches/ plaques
- Koebner phenomenon
 - Appearance of psoriasis in sites of skin trauma or pressure e.g. scratch marks, operation sites .
 - Present in lichen planus, vitiligo, viral wart
- “Atypical” with no scaling in moist flexural intertriginous area

Chronic Plaque Psoriasis

- Most Common Variant
- Plaques may be as large as 20 cm
- Symmetrical disease
- Sites of Predilection
 - Elbows
 - Knees
 - Presacrum
 - Scalp
 - Hands and Feet

Chronic Plaque Psoriasis

- May be widespread – up to 80% BSA
- Genitalia involved in up to 30% of patients
- Most patients have nail changes
 - Nail pitting
 - “Oil Spots”
 - Involvement of the entire nail bed
 - Onychodystrophy
 - Loss of nail plate

□Auspitz's sign:

- light scraping of the scale with a wooden spatula produces multiple bleeding points
- extreme thinning of the epidermis over the capillary laden dermal papillae

Koebner phenomenon

- Appearance of psoriasis in sites of skin trauma or pressure e.g. scratch marks, operation sites .
- Present in : lichen planus, vitiligo, viral wart

Scalp Psoriasis

- Common
- Well demarcated erythematous silvery scaly plaque with normal skin intervening
- Post-auricular area commonly involved
- Non scarring alopecia when severe, regrow when condition improve
- DDx with seborrhoeic dermatitis by presence of typical plaque elsewhere +/- psoriatic nail changes

Palmoplantar Psoriasis

- Common
- Indurated heavily scaled plaque +/- fissuring
- Well-demarcated
- DDx with foot/ hand eczema

Nail Psoriasis

- ~50% of psoriasis have nail changes
- Pitting
- Onycholysis (separation of nail plate from nail bed)
- Oil drop sign (a yellow brown, subungual spot surrounded by erythema)
- Subungual hyperkeratosis
- Secondary onychomycosis is common

Guttate Psoriasis

- Latin “gutta” means a drop
- Mainly affects children and young adults
- Characterized by numerous 0.5 to 1.5 cm papules /plaques
- Very small plaques generalized with centripetal distribution
- May coalescent into larger plaques
- Preceded by streptococcal tonsillitis or pharyngitis 2 weeks before onset
- Spontaneous remissions in children
- Often chronic in adults

Flexural Psoriasis

- Psoriasis affecting axillae, perineum and umbilicus
- Atypical psoriasis as friction & humidity removes the scale (diagnostic confusion)
- Irritating when sweating

Life–Threatening Forms of Psoriasis

- Generalized Pustular Psoriasis
- Erythrodermic Psoriasis

Palmoplantar Pustular Psoriasis

- Relatively uncommon variant
- Painful, sterile pustules develop within plaque at palms and soles
- Pustules resolve to leave post inflammatory hyperpigmentation
- Female predominance
- 20% associated with psoriasis elsewhere
- Almost exclusively associated with smoking
- Resistant to topical treatment

Generalized Pustular Psoriasis

- Von Zumbusch's disease
- Erythematous edematous plaques studded with monomorphic sterile pustules. often after short episodes of fever of 39° to 40°C
- Weight loss , Muscle Weakness, Hypocalcemia
Leukocytosis , Elevated ESR
- Precipitated by :
 - withdrawal of oral steroid or widespread use of ultra potent topical steroid
 - pregnancy
 - Can be life-threatening due to fluid loss, sepsis

Erythrodermic Ps.

- Universal redness & scaling
- Often nail & hair growth disturbance
- May be an end-result of acute Ps.
- Exfoliative Ps.
 - Unwell, fever, leucocytosis
 - Excessive of body heat & hypothermia
 - Inc. cut. blood flow ⇒ high card. output
⇒ heart failure
 - Inc. percutaneous loss of water ⇒ Inc. loss of protein & iron (through scales) ⇒ hypoproteinaemia & iron deficiency anaemia.
- Increase epidermal permeability ?? topical steroids

Erythrodermic Psoriasis

- >90% of BSA affected
- Life threatening with transcutaneous fluid loss, temperature dysregulation, sepsis, high output, cardiac failure
- Other DDx of erythroderma-
atopic eczema, drug eruption
, cutaneous T cell lymphoma, pityriasis rubra pilaris

Erythrodermic Psoriasis

- Triggering Factors
 - Systemic Infection
 - Withdrawal of high potency topical or oral steroids
 - Withdrawal of Methotrexate
 - Phototoxicity
 - Irritant contact dermatitis

Drug-provoked (Induced) psoriasis: Reported agent

MOST COMMONLY ASSOCIATED AGENTS

Beta blockers

Lithium

Antimalarial

Nonsteroidal Anti-Inflammatory Drugs

Psoriatic Arthritis

- ~10% of chronic plaque psoriasis
- Only ~15% of cases with skin and joint disease begin simultaneously
- ~60% of skin disease precedes arthritis
- ~25% of arthritis precedes skin disease
- Probably a positive correlation between severity of skin disease and arthritis developing
- Association: HLA B27: sacro-ileitis;
- B38 and DR7: peripheral arthritis;
- B39: all types;
- DR4: symmetrical arthritis

5 Types of Psoriatic Arthropathy


- Classical distal arthropathy-distal IP joint
- Seronegative RA-like polyarthritits
- Oligoarticular asymmetrical arthritis
- Spondyloarthropathy- Ankylosing spondylitis-like
- Arthritis mutilans

Psoriatic Arthritis treatment

- NASIDs- may exacerbate psoriasis
- Methotrexate
- Sulphasalazine
- Cyclosporine
- Systemic steroid- may make the skin lesions more difficult to control
- Biologics

Histopathological changes

- Inflammation
- Epidermal keratinocyte hyperproliferation
- (parakeratosis) incomplete cornification of keratinocytes with retention of nuclei
- (acanthosis), irregular thickening of the epidermis over the rete ridges but thinning over dermal papillae
- (munro abscesses) epidermal polymorphonuclear leucocyte infiltrates
- Vascular proliferation :dilated capillary loops in the dermal papillae



hyper/parakeratosis

diminished granular layer

thin suprapapillary plates

lichenoid: have huge granular layer

elongated rete ridges

Lymphocytic infiltrate


Confluent parakeratosis

Suprapapillary thinning

Spongiform pustule

Clubbed rete ridge

A




Munro microabscess

Acanthosis

Dilated capillary

Perivascular lymphocytes

B



Laboratory findings

- Elevated uric acid
- Mild anemia
- Negative nitrogen balance
- Increase sedimentation rate
- Increase alpha-2-microglobulin
- Increase IgA and IgA immune complex

Differential diagnosis

Erythroderma

- Atopic dermatitis
- Sezary syndrome
- Drug eruption
- Generalized contact dermatitis

Intertrigenous psoriasis

- Candidiasis
- Contact dermatitis
- Darier's disease

Differential diagnosis

Psoriasis vulgaris

- Nummular eczema
- Mycosis fungoides, plaque stage
- Tinea corporis

Guttate psoriasis

- Pityriasis rosea
- Pityriasis lichenoides et varioliformis
- Syphillis
- Tinea corporis

Differential diagnosis

Nail psoriasis

- Tinea unguium
- Dyskeratosis : secondary to injury

Scalp and face

- Seborrheic dermatitis

Genitalia

- In situ squamous cell CA

Current Treatment Approaches

Treatment Options

- Monotherapy
 - Combination therapy
 - Rotational therapy
 - Sequential therapy

Treatment of Psoriasis

- **What influences therapy choice?**
 - **Clinical type and severity of psoriasis (eg, mild vs moderate-to-severe), assessed by Psoriasis Area and Severity Index (PASI)**
 - **Response to previous treatment**
 - **Therapeutic options**
 - **Patient preference**
- **The "1-2-3" step approach is no longer generally accepted for disease more than mild in severity**
 - **Level 1: Topical agents—do not work**
 - **Level 2: "Phototherapy"—difficult; not always available**
 - **Level 3: Systemic therapy**
- **Risk in relation to benefit must be evaluated**

Topical Agents

- Initial therapeutic choice for mild-to-moderate psoriasis
 - Emollients
 - Keratolytics (salicylic acid, lactic acid, urea)
 - Coal tar
 - Anthralin
 - Vitamin D₃ analogues (calcipotriene)
 - Corticosteroids
 - Retinoids (tazarotene, acitretin)
- Compliance can be difficult due to amount of time required to apply topicals 2 to 4 times/day

Systemic Therapy

- Systemic therapy should be reserved for patients with disabling psoriasis despite topical therapy
 - Psoralen + UVA light
 - Oral retinoids: acitretin (+/- phototherapy)
 - Methotrexate
 - Cyclosporine

Phototherapy

- Used to treat moderate-to-severe psoriasis
- Phototherapy causes death of T cells in the skin
 - Natural sunlight
 - Ultraviolet (UV) B light
 - UVB light + coal tar (Goeckerman treatment)
 - Best therapeutic index for moderate-to-severe disease
 - UVB light + anthralin + coal tar (Ingram regimen)
 - Usually 3 treatments/week for 2 to 3 months is needed
 - Accessibility to a light box facility and compliance necessary

UVA Light With Psoralen (PUVA)

- Psoralen is a drug that causes a toxic reaction to skin lymphocytes when it is activated by UVA light
- Psoralen can be given systemically or topically
- Effective treatment—longest remissions of any treatment available
- Adverse effects
 - Nausea, burning, pruritus
 - Risk of cancer with cumulative use—both squamous cell carcinoma and melanoma
 - >160 cumulative treatments

Methotrexate

- **Folic acid metabolite**
 - Blocks deoxyribonucleic acid synthesis, inhibits cell proliferation
- **Dose**
 - Start at about 15 mg/week; maximum 30 mg/week
 - Can also be given intramuscularly
- **Adverse effects**
 - Headache, nausea, bone marrow suppression
 - Cumulative dose predictive of liver toxicity
 - Prospectively identify risk factors for liver disease
 - Guidelines recommend liver biopsy after 1.5 g
 - Teratogenic in men and women

Acitretin: Oral Retinoid


- Frequently used in combination with topical agents, systemic therapies, and UV light
- Less effective as monotherapy for plaque psoriasis
- Plaque psoriasis dose
 - Start at 10 to 25 mg/day
- Adverse effects (fewest dose-related adverse effects)
 - Peeling/dry skin, alopecia, muscle pain
 - Lipid abnormalities
- Teratogenic: avoid pregnancy

Cyclosporine

- Reserved for severe, recalcitrant disease
- Inhibits the proliferation of activated T cells
- Dose: 4 mg/kg/day, not to exceed 5 mg/kg/day
 - Tapering slowly may improve remission
- Use not recommended for >1 year
 - Renal toxicity
- Patients relapse 2 to 4 months after discontinuing
- Adverse effects
 - Immunosuppression: infections, possible malignancy
 - Hirsutism, gingival hyperplasia, muscle pain, infection
 - Serious: hypertension, renal failure

Rotational/Sequential Treatment

- Therapeutic strategy for moderate-to-severe disease
 - Switch to alternative therapy before early evidence of toxicity



New Treatments

Biologic Therapies Currently Approved for the Treatment of Psoriasis

Alefacept

Efalizumab

Etanercept

Systemic Treatment of Psoriasis

Currently licensed biologics for psoriasis

<u>Type Drug</u>	<u>Route</u>	<u>Dosing</u>	<u>Freq PlasmaHalf-life</u>
------------------	--------------	---------------	-----------------------------

Adalimumab

TNF- α inhibitor

Subcutaneous

80mg 1st week, then 40mg 2nd wk , Then Every 2 wk

2 weeks

Etanercept

Subcutaneous

50mg (0.8mg/kg, max 50mg)

First 12 week: twice a wk Then once aweek

70 hours

Infliximab

IL-12/23Antibody

Intravenous

5mg/kg

0,2,6 wk, then every 8 wk8-9.

5days

Ustekinumab

Subcutaneous

**45mg for <100 kg 90mg for >100kg 0,4 wk, then every 12 wk
15-32days**

Absolute Contraindications:

Pregnancy/breastfeeding

Active (chronic) infections (including tuberculosis and active chronic hepatitis B)

Congestive heart failure (NYHA grade III or IV)

Relative contraindications

History of recurrent infections

PUVA >200 treatments (especially if followed by cyclosporin use)

HIV or AIDS

Hepatitis C

Congestive heart failure (NYHA grade I or II)

SLE, Demyelinating disease

Malignancies or lymphoproliferative disorders

Live vaccines

Treatment Modalities:

- Combination therapy
 - –contraindicated in additive increase risk/ S/E, e.g.
 - Phototherapy +CsA increase risk of cutaneous cancer
 - Acitretin +MTX increase risk of hepatotoxicity

Treatment Modalities:

- Rotational therapy
 - use of therapies for a specified period (e.g. 1–2 year) then rotate to an alternative therapy to minimize long-term toxicity in any given therapy and decrease therapy resistance/ tachyphylaxis

Treatment Modalities:

- Sequential therapy–
 - Induction phase: use stronger potentially more toxic agents to clear psoriasis initially
 - e.g. Ultrapotent topical steroid or CsA
 - Transitional phase
 - e.g. OM steroid+ Nocte calcipotriol or acitretin
 - Maintenance phase: use of a “weaker”, less toxic agent for maintenance
 - e.g. weekday calcipotriol +weekend steroid or acitretin +/-UVB/ PUVA

PITYRIASIS ROSEA

Pityriasis Rosea

Acute, self-limiting, mild inflammatory exanthem of unknown origin.

Etiology:

- Unknown
- A virus infection is most frequently suggested?
 - The formation of herald patch
 - The self-limited course
 - The seasonal preponderance & rare recurrence
- The Pit. rosea-like may occur as a reaction to:
 - Captopril
 - Gold
 - Clonidine
 - Barbiturates
 - Arsenicals
 - Bismuth
 - Methoxypromazine

Epidemiology:

In children and young adult

- Increased incidence in spring and autumn**
- PR has been estimated to account for 2% of dermatologic outpatient visits**
- PR is more common in women than in men**

Pathophysiology:

- PR considered to be a viral exanthem**
- Immunologic data suggest a viral etiology**
- Families and close contacts**
- A single outbreak tends to elicit lifelong immunity**
- Human herpesvirus (HHV)–7and HHV-6**
- PR-like drug eruptions may be difficult to distinguish from non–drug-induced cases**
- Captopril, metronidazole, isotretinoin, penicillamine, bismuth, gold, barbiturates, and omeprazole**

- Begins with a solitary macule that heralds the eruption(herald spot/patch)
- Usually a salmon-colored macule
- Over a few days it become a patch with a collarette of fine scale just inside the well-demarcated border
- Within the next 1-2 weeks, a generalized exanthem usually appears
- Bilateral and symmetric macules with a collarette scale oriented with their long axes along cleavage lines
- Tends to resolve over the next 6 weeks
- Pruritus is common, usually of mild-to-moderate severity
- Over trunk and proximal limbs

Pityriasis Rosea

Clinical features

- **Salmon-colored papular & macular lesions**
- **oval or hexagonal patches or circinate covered with finely crinkled, dry epidermis ⇒ often desquamates**
- **Usually begins with a single - herald or mother patch**
- **The new lesions spread rapidly**
- **Arranged - runs parallel to the lines of cleavage**
- **Generalized, affecting the trunk & sparing the sun-exposed surfaces**
- **Moderate pruritus may be present**
- **Variations in the mode of onset, course and clinical manifestations are common (papular Pit. Rosea)**

Atypical form of PR :

Occurs in 20% of patients

Inverse PR

Unilateral variant

Papular PR

Erythema multiforme–like

Purpuric PR

Differential Diagnosis :

Viral exantheme

Drug Eruption

Lichen Planus

Psoriasis, Guttate

Syphilis

Tine Corporis

Seborrheic Dermatitis

Nummular Dermatitis

Pityriasis Lichenoides

Pityriasis Rosea

Treatment

- Prevent irritable hot baths & soaps and woolen clothes
- Symptomatic
- Emollients
- Corticosteroid (Topical, Oral, IM)
- UVB

Lichen planus (LP)

Background:

- Lichen planus (LP) is a pruritic, papular eruption characterized by its violaceous color; polygonal shape; and, sometimes, fine scale**
- It is most commonly found on the flexor surfaces of the upper extremities, on the genitalia, and on the mucous membranes.**

Lichen Planus & Lichenoid Eruption

- Inflammatory pruritic disease of the skin and mucous membranes
- Rare in children
- Etiology:
 - The cause of LP remains unknown
 - ?? an alteration of epidermal cell antigens induce a cell mediated immune response
 - ?? may be familial (early age & chronic)
 - Drugs ⇒ may induce lichenoid reactions (e.g. antimalarials, thiazide derivatives, propranolol..)
 - Viral infection? Symmetrically associated with viral hepatitis
 - A psychogenic origin? Severe psychic trauma
 - An auto-immune phenomenon?

Epidemiology :

- Approximately 1% of all new patients seen at health care clinics**
- Rare in children**
- F=M**
- No racial predispositions have been noted**
- LP can occur at any age but two thirds of patients are aged 30-60 years**

Pathophysiology :

The cause of LP is unknown


-LP may be a cell-mediated immune response of unknown origin

-LP may be found with other diseases of altered immunity like ulcerative colitis, alopecia areata, vitiligo, dermatomyositis

-An association is noted between LP and hepatitis C virus infection ,chronic active hepatitis, and primary biliary cirrhosis

-Familial cases

-Drug may induce lichenoid reaction like thiazide,antimalarials,propranolol



Lichen Planus: Multifactorial Cause

Clinical Features :

Most cases are insidious

-The initial lesion is usually located on the flexor surface of the limbs

-After a week or more, a generalized eruption develops with maximal spreading within 2-16 weeks-

-Pruritus is common but varies in severity

-Deep pigmentations may persist for long time.

-Oral lesions may be asymptomatic or have a burning sensation

-In more than 50% of patients with cutaneous disease, the lesions resolve within 6 months, and 85% of cases subside within 18 months

- The papules are violaceous, shiny, and polygonal; varying in size from 1 mm to greater than 1 cm in diameter
- They can be discrete or arranged in groups of lines or Circles
- Characteristic fine, white lines, called Wickham stria, are often found on the papules
- Oral lesions are classified as reticular, plaquelike, atrophic, papular, erosive, and bullous
- Ulcerated oral lesions may have a higher incidence of malignant transformationO(the development of squamous cell carcinoma)
- Genital involvement is common in men with cutaneous disease
- Vulvar involvement can range from reticulate papules to severe erosions

- Wickham's striae:
Grayish puncta or streaks which form a network on the surface of the papules (focal increase in thickness of granular layer & infiltrate)
- Koebner's isomorphic phenomenon:
As in psoriasis by physical trauma (scratching) skin lesions are produced in the scratch marks identical to those already on the pat. skin.
- Pruritus:
 - It is intolerable in acute cases
 - Most pat. react by rubbing rather than scratching

Clinical types:

✓ Hypertrophic LP

-These extremely pruritic lesions are most often found on the extensor surfaces of the lower extremities, especially around the ankles

✓ Atrophic LP

-is characterized by a few lesions, which are often the resolution of annular or hypertrophic lesions

✓ Erosive LP

✓ Follicular LP

-keratotic papules that may coalesce into plaques
-A scarring alopecia may result

✓ Annular LP

Annular lesions with an atrophic center can be found on the buccal mucosa and the male genitalia

✓ Vesicular and bullous LP

-develop on the lower limbs or in the mouth from preexisting LP lesions

✓ Actinic LP

-Africa, the Middle East, and India

-mildly pruritic eruption

-characterized by nummular patches with a hypopigmented zone surrounding a hyperpigmented center

✓ LP pigmentosus

-common in persons with darker-pigmented skin

-usually appears on face and neck

LP and Nails

**In 10% of patients
nail plate thinning causes longitudinal grooving and
ridging
subungual hyperkeratosis, onycholysis
Rarely, the matrix can be permanently destroyed with
prominent pterygium formation
twenty-nail dystrophy**

Differential diagnosis

- Papular syphilis
- Guttate psoriasis
- Lichenoid forms of (eczema, scabies)
- Pityriasis rosea
- Leukoplakia (mucous m.)

Management :

self-limited disease that usually resolves within 8-12 months

-Anti-histamine

-topical steroids, particularly class I or II ointments

-systemic steroids for symptom control and possibly more rapid resolution

-Oral acitretin

-Photo-therapy

-Others

